Long-Term Effects of Intensive Glucose Lowering on Cardiovascular Outcomes
Open accessThe DOI matches its Crossref record; 18 of the 18 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Intensive glucose lowering has previously been shown to increase mortality among persons with advanced type 2 diabetes and a high risk of cardiovascular disease. This report describes the 5-year outcomes of a mean of 3.7 years of intensive glucose lowering on mortality and key cardiovascular events. METHODS: We randomly assigned participants with type 2 diabetes and cardiovascular disease or additional cardiovascular risk factors to receive intensive therapy (targeting a glycated hemoglobin level below 6.0%) or standard therapy (targeting a level of 7 to 7.9%). After termination of the intensive therapy, due to higher mortality in the intensive-therapy group, the target glycated hemoglobin level was 7 to 7.9% for all participants, who were followed until the planned end of the trial. RESULTS: Before the intensive therapy was terminated, the intensive-therapy group did not differ significantly from the standard-therapy group in the rate of the primary outcome (a composite of nonfatal myocardial infarction, nonfatal stroke, or death from cardiovascular causes) (P=0.13) but had more deaths from any cause (primarily cardiovascular) (hazard ratio, 1.21; 95% confidence interval [CI], 1.02 to 1.44) and fewer nonfatal myocardial infarctions (hazard ratio, 0.79; 95% CI, 0.66 to 0.95). These trends persisted during the entire follow-up period (hazard ratio for death, 1.19; 95% CI, 1.03 to 1.38; and hazard ratio for nonfatal myocardial infarction, 0.82; 95% CI, 0.70 to 0.96). After the intensive intervention was terminated, the median glycated hemoglobin level in the intensive-therapy group rose from 6.4% to 7.2%, and the use of glucose-lowering medications and rates of severe hypoglycemia and other adverse events were similar in the two groups. CONCLUSIONS: As compared with standard therapy, the use of intensive therapy for 3.7 years to target a glycated hemoglobin level below 6% reduced 5-year nonfatal myocardial infarctions but increased 5-year mortality. Such a strategy cannot be recommended for high-risk patients with advanced type 2 diabetes. (Funded by the National Heart, Lung and Blood Institute; ClinicalTrials.gov number, NCT00000620.).
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Those levels predict the risk of cardiovascular disease.”
From Endpoints for geroscience clinical trials: health outcomes, biomarkers, and biologic age (2022) · cites this paper as [14]
Experimental — accuracy not yet measuredThe check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“Diabetic kidney disease might also play a role in the arrhythmia-associated mechanism of sudden death in this setting.655”
From 2023 ESC guidelines for the management of cardiovascular disease in patients with diabetes. (2023) · cites this paper as [655]
Experimental — accuracy not yet measuredIn the citing paper
“However, the belief that HbA1c was a surrogate marker was contradicted by findings from the ACCORD trial that diabetics randomly assigned to intensive treatment that reduced HbA1c levels in fact increased the risk of CVD events [14].”
From Endpoints for geroscience clinical trials: health outcomes, biomarkers, and biologic age (2022) · cites this paper as [14]
In the citing paper
“For example, intensive hypoglycemic treatments, such as oral hypoglycemics and insulin, substantially reduce fasting glucose and HbA1c levels.”
From Endpoints for geroscience clinical trials: health outcomes, biomarkers, and biologic age (2022) · cites this paper as [14]
In the citing paper
“Similar U-shaped curves were found in a 7-year observational study of persons with T1D and a 22-year observational study of >20,000 persons with T2D.83,84”
From American Association of Clinical Endocrinology Clinical Practice Guideline: Developing a Diabetes Mellitus Comprehensive Care Plan-2022 Update. (2022) · cites this paper as [83]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Effects of Intensive Glucose Lowering in Type 2 Diabetes
(2008) · New England Journal of Medicine · doi:10.1056/nejmoa0802743 · Cited by 7,888
Self-citation10-year follow-up of intensive glucose control in type 2 diabetes
Holman, R. R., Paul, S. K., Bethel, M. A., Matthews, D. R., & Neil, H. A. W. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0806470 · Cited by 7,751
Effects of intensive blood-pressure control in type 2 diabetes mellitus
(2010) · New England Journal of Medicine · doi:10.1056/nejmoa1001286 · Cited by 3,598
Self-citationEffects of Combination Lipid Therapy in Type 2 Diabetes Mellitus
(2010) · New England Journal of Medicine · doi:10.1056/nejmoa1001282 · Cited by 2,837
Self-citationGlycated hemoglobin, diabetes, and cardiovascular risk in nondiabetic adults
Selvin, E., Steffes, M. W., Zhu, H., Matsushita, K., Wagenknecht, L., Pankow, J., Coresh, J., & Brancati, F. L. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa0908359 · Cited by 1,544
Huxley, R., Barzi, F., & Woodward, M. (2006) · BMJ · doi:10.1136/bmj.38678.389583.7c · Cited by 1,534
The J-Curve Phenomenon in Hypertension
Kang, Y.-Y., & Wang, J.-G. (2016) · Pulse · doi:10.1159/000446922 · Cited by 1,530
Gerstein, H. C., Miller, M., & Byington, R. P. (2010) · Cited by 981
Bonds, D. E., Miller, M. E., Bergenstal, R. M., Buse, J. B., Byington, R. P., Cutler, J. A., Dudl, R. J., Ismail-Beigi, F., Kimel, A. R., Hoogwerf, B., et al. (2010) · BMJ · doi:10.1136/bmj.b4909 · Cited by 933
Miller, M. E., Bonds, D. E., Gerstein, H. C., Seaquist, E. R., Bergenstal, R. M., Calles-Escandon, J., Childress, R. D., Craven, T. E., Cuddihy, R. M., Dailey, G., et al. (2010) · BMJ · doi:10.1136/bmj.b5444 · Cited by 429
Cited by
Items 701–800 of 1,000
Antidiabetic Treatment Patterns in a Medicare Advantage Population in the United States
Slabaugh, S. L., Xu, Y., Stacy, J. N., Baltz, J. C., MEAH, Y. A., Lian, J., Moretz, D. C., & Bouchard, J. R. (2015) · Drugs & Aging · doi:10.1007/s40266-014-0235-8 · Cited by 5
Novedades en cardiología clínica: nuevos enfoques de viejos retos
Borràs, X., Murga, N., Ripoll, T., & Gómez‐Doblas, J. J. (2012) · Revista Española de Cardiología · doi:10.1016/j.recesp.2011.10.033 · Cited by 5
Cardiovascular Disease in Women
Bhakta, M. D., Mookadam, F., & Wilansky, S. (2011) · Future Cardiology · doi:10.2217/fca.11.30 · Cited by 4
Shomali, M. E. (2011) · Journal of Community Hospital Internal Medicine Perspectives · doi:10.3402/jchimp.v1i2.7217 · Cited by 5
“From an outpatient standpoint, the ACCORD study also showed increased cardiovascular mortality in an intensively treated population of patients with DM2 (7).”
BackgroundNeue Therapieoptionen mit kontinuierlich gemessenen Glukosedaten – Empfehlungen für die Praxis
Seufert, J., Deiss, D., Gölz, S., Haak, T., Klausmann, G., Kroeger, J., Lobmann, R., Pfeiffer, A. F. H., Schnell, O., Seibold, A., et al. (2019) · Diabetologie und Stoffwechsel · doi:10.1055/a-0978-4537 · Cited by 4
“N Engl J Med 2008; 358: 2545–2559 [43] Gerstein HC, Miller ME, Genuth S et al.”
BackgroundPosition statement of the SEMI, SED, redGDPS, SEC, SEEDO, SEEN, SEMERGEN y SEMFYC
Huelgas, R. G., Peralta, F. G., Fernández, L. C., Galve, E., Casanueva, F. F., Puig‐Domingo, M., Bravo, J. J. M., Beltrán, D. O., Muñoz, J. E., Torre, E. L. M., et al. (2015) · Revista Clínica Española (English Edition) · doi:10.1016/j.rceng.2015.09.004 · Cited by 5
Understanding insulin management: Role of the pharmacist
Haines, S. T., & Neumiller, J. J. (2014) · Pharmacy Today · doi:10.1016/s1042-0991(15)30967-1 · Cited by 6
Intensifying Treatment Beyond Monotherapy in Type 2 Diabetes Mellitus: Where Do Newer Therapies Fit?
Kühn, A., Park, J., Ghazi, A., & Aroda, V. R. (2017) · Current Cardiology Reports · doi:10.1007/s11886-017-0832-3 · Cited by 4
Optimal search strategies for identifying moderators and predictors of treatment effects in PubMed
Tummers, M., van Hoorn, R., Levering, C., Booth, A., van der Wilt, G. J., & Kievit, W. (2018) · Health Information & Libraries Journal · doi:10.1111/hir.12230 · Cited by 5
Akın, S., Bölük, C., Ozgur, Y., Aladağ, N., Geçmez, G., Keskin, O., Boru, U. T., & Tasdemir, M. (2019) · Acta Endocrinologica (Bucharest) · doi:10.4183/aeb.2019.311 · Cited by 4
“The ACCORD study also recorded an increase in cardiovascular and all-cause mortality risk caused by tight glycemic control (8).”
BackgroundNaser, A. Y., Alsairafi, Z. K., Alwafi, H. H., Turkistani, F. M., Bokhari, N. S., Alenazi, B., Dahmash, E. Z., & Alyami, H. S. (2020) · International Journal of Clinical Practice · doi:10.1111/ijcp.13662 · Cited by 5
Biomarkers associated with severe hypoglycaemia and death in ACCORD
Chow, L. S., CHEN, H.-Y. P., Miller, M. E., Marcovina, S. M., & Seaquist, E. R. (2015) · Diabetic Medicine · doi:10.1111/dme.12883 · Cited by 4
Glycaemic index in chronic disease
Augustin, L. S. A. (2013) · Nutrafoods · doi:10.1007/s13749-013-0061-3 · Cited by 4
Griffin, S. (2012) · Annals of Medicine · doi:10.3109/07853890.2012.679959 · Cited by 4
Kim, S., Kim, B.-J., Lim, D.-M., Song, I.-G., Jung, J. H., Lee, K.-W., Park, K., Cho, Y.-Z., Lee, D.-H., & Koh, G. P. (2011) · Diabetes & Metabolism Journal · doi:10.4093/dmj.2011.35.2.190 · Cited by 6
“However, recent studies have reported that while the use of intensive therapy to target glycated hemoglobin levels below 6% reduces 5-year nonfatal myocardial infarctions, it increases 5-year mortality [3].”
BackgroundHeng, X.-P., Yang, L., Chen, M., Li, L., Huang, S.-P., & Lei, Y. (2015) · Chinese Journal of Integrative Medicine · doi:10.1007/s11655-015-0780-5 · Cited by 4
Flaws in Current Clinical Trial Design: Need for Intermediate Markers
Yeboah, J. (2011) · Journal of Postgenomics Drug & Biomarker Development · doi:10.4172/2153-0769.1000102e · Cited by 4
“The ILLUMINATE [1], AIM HIGH and ACCORD [2] trials among others have unfortunately showed that this assumption may be wrong.”
MethodThink Health � Speak Health � Achieve Health
Sturmberg, J. P. (2013) · OA Family Medicine · doi:10.13172/2052-8922-1-1-345 · Cited by 5
Solomon, D. H., Yu, Z., Katz, J. N., Bitton, A., Corrigan, C., Fraenkel, L., Harrold, L. R., Smolen, J. S., Losina, E., & Lü, B. (2018) · Arthritis Care & Research · doi:10.1002/acr.23755 · Cited by 4
“One trial that tested a TTT intervention for diabetes mellitus showed an increased risk of hypoglycemia and death when using a target glycosylated hemoglobin level (HbA1C) (5).”
BackgroundCardiovascular outcome trials of glucose-lowering strategies in type 2 diabetes–Authors' reply
Holman, R. R., Sourij, H., & Califf, R. M. (2014) · The Lancet · doi:10.1016/s0140-6736(14)61674-3 · Cited by 5
Peter, R., Bajwa, H. A., & Anthony, S. (2013) · Current Opinion in Lipidology · doi:10.1097/mol.0b013e32835ec5f5 · Cited by 4
Fairman, K. A. (2011) · Journal of Managed Care Pharmacy · doi:10.18553/jmcp.2011.17.3.224 · Cited by 4
“5%).(13,14) Specifically, among patients treated with the intensive strategy for a mean of 3.”
Blood Pressure Control in Older Adults: Toward a More Personalized Medicine Approach
Williamson, J. D. (2020) · Journal of the American Geriatrics Society · doi:10.1111/jgs.16750 · Cited by 4
“In both cases, expert experience and observational evidence suggested the opposite of what the randomized clinical trial discovered.(8,9) Another example of this is the recent SPRINT result that showed an intensive systolic BP treatment goal of 120 mm Hg was superior to a treatment goal of 140 mm Hg in ambulatory olde…”
ResultWang, H., Liu, J., & Zhao, H. (2015) · Drug Design Development and Therapy · doi:10.2147/dddt.s53048 · Cited by 3
Gumprecht, J. J., Lip, G. Y. H., Sokal, A., Średniawa, B., Stokwiszewski, J., Zdrojewski, T. R., Rutkowski, M., Grodzicki, T. K., Kaźmierczak, J., Opolski, G., et al. (2023) · Scientific Reports · doi:10.1038/s41598-023-43939-5 · Cited by 3
Basu, A., Montano‐Campos, F., Huang, E. S., Laiteerapong, N., & Barthold, D. (2024) · Diabetes Obesity and Metabolism · doi:10.1111/dom.15878 · Cited by 3
“5,6 Over the past decade, the number of available glucose-lowering agents has expanded, creating more options as well as uncertainty regarding the optimal approach to glucose control.”
Liu, M., Pei, J., Zeng, C. C., Xin, Y., Tang, P., & Hu, X. (2025) · Scientific Reports · doi:10.1038/s41598-025-08580-4 · Cited by 3
Królewski, A. S., Haukka, J. K., Dom, Z. I. M., Curovic, V. R., Wu, C., Morieri, M. L., Ihara, K., Tye, S. C., Kobayashi, H. H., Keum, Y., et al. (2025) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.0000000863 · Cited by 7
Rapid-acting insulin glulisine: an update on clinical experience
DAILEY, G. E. (2011) · Expert Review of Endocrinology & Metabolism · doi:10.1586/eem.11.40 · Cited by 4
Empagliflozin reduces cardiovascular events and mortality in type 2 diabetes
Guthrie, R. M. (2016) · Postgraduate Medicine · doi:10.1080/00325481.2016.1174566 · Cited by 3
“ACCORD actually showed the intensive treatment group had an increase in the total mortality and in cardiovascular mortality over the moderately controlled glucose.[8] ADVANCE was a similar study with an intensive glycated hemoglobin target level of 6.”
ResultLovre, D., Htun, W., Carrion, C., & Fonseca, V. A. (2016) · Current Diabetes Reports · doi:10.1007/s11892-016-0788-5 · Cited by 3
How to measure the net benefit of treatment?
Gueyffier, F., Piedbois, P., Bergmann, J., Avouac, B. P., Borel, T., Boussageon, R., Brun-Strang, C., Braunstein, D., Cazeneuve, B., Diviné, M., et al. (2017) · Therapies · doi:10.1016/j.therap.2016.12.004 · Cited by 5
Statement for Diabetes Guideline Has Been on Discussion for Future Better Lives
Bando, H. (2018) · Journal of Endocrinology and Thyroid Research · doi:10.19080/jetr.2018.03.555616 · Cited by 3
Wass, J., Owen, K. R., & Turner, H. E. (2014) · Oxford University Press eBooks · doi:10.1093/med/9780199644438.003.0013 · Cited by 3
Kutz, A., Kim, D. H., Liu, J., Munshi, M. N., & Patorno, E. (2025) · Diabetes Care · doi:10.2337/dc24-1795 · Cited by 3
Testai, F. D., & Gorelick, P. B. (2010) · Humana Press eBooks · doi:10.1007/978-1-60761-010-6_12 · Cited by 3
Kakorin, S. V., Iskandaryan, R. A., & Mkrtumyan, A. M. (2016) · Diabetes Mellitus · doi:10.14341/dm2003422-27 · Cited by 5
Assessing the Population Impact of Published Intervention Studies
Coffinier, C., Teutsch, S. M., & Fielding, J. E. (2015) · NAM Perspectives · doi:10.31478/201506e · Cited by 3
“New England Journal of Medicine 364(11):1016–1026.”
Kyavar, M., & Alemzadeh‐Ansari, M. J. (2017) · Elsevier eBooks · doi:10.1016/b978-0-323-51149-0.00035-3 · Cited by 3
Hanefeld, M., Fleischmann, H., Liebl, A., & Siegmund, T. (2019) · Diabetologie und Stoffwechsel · doi:10.1055/a-0820-1665 · Cited by 3
“Acta Diabetol 2013; 50: 587–595 [66] Gerstein HC, Miller ME, Accord Study Group et al.”
BackgroundNodari, S., Fioretti, F., & Barillà, F. (2022) · Heart Failure Reviews · doi:10.1007/s10741-021-10203-9 · Cited by 6
Pincus, S. H., Kyro, A., Maresh, G. A., Peters, T. R., Kempa, J., Marcotte, T. K., Gao, Z., Ye, J., Copié, V., & Song, K. (2022) · Toxins · doi:10.3390/toxins14120820 · Cited by 3
Pretta, A., Ziranu, P., Giampieri, R., Donisi, C., Cimbro, E., Spanu, D., Lai, E., Pecci, F., Balconi, F., Lupi, A., et al. (2022) · Digestive and Liver Disease · doi:10.1016/j.dld.2022.11.012 · Cited by 3
Type 2 diabetes: recent advances in diagnosis and management
Chatterjee, S., & Davies, M. J. (2015) · Prescriber · doi:10.1002/psb.1355 · Cited by 3
Proposal for the administration of metformin in patients with chronic kidney disease
Balogh, Z., & Mátyus, J. (2012) · Orvosi Hetilap · doi:10.1556/oh.2012.29448 · Cited by 4
Les hypoglycémies chez les diabétiques âgés : conséquences sur les fonctions cognitives
Bauduceau, B., Doucet, J., & Bordier, L. (2011) · Médecine des Maladies Métaboliques · doi:10.1016/s1957-2557(11)70270-x · Cited by 4
Beneficial and Detrimental Effects of Glycemic Control on Cardiovascular Disease in Type 2 Diabetes
Taub, P. R., Higginbotham, E., & Henry, R. R. (2013) · Current Cardiology Reports · doi:10.1007/s11886-012-0332-4 · Cited by 3
Report of the 20th European Stroke Conference, Hamburg, May 24–27, 2011
Hennerici, M. G. (2011) · Cerebrovascular Diseases · doi:10.1159/000334176 · Cited by 3
Diabetesmanagement in der Klinik
Tafel, J., Buerstell, M., Leippert, C., Benack, E., Stelling, A., & Jaeger, C. (2011) · Der Diabetologe · doi:10.1007/s11428-011-0750-8 · Cited by 3
The Influence of Biostatistics at the National Heart, Lung, and Blood Institute
DeMets, D. L., Wittes, J. T., & Geller, N. L. (2015) · The American Statistician · doi:10.1080/00031305.2015.1035962 · Cited by 3
Inzucchi, S. E., Bergenstal, R. M., Buse, J. B., Diamant, M., Ferrannini, E., Nauck, M. A., Peters, A. L., Τσάπας, Α., Wender, R. C., & Matthews, D. R. (2012) · Cited by 3
Agarwal, S., Parashar, A., & Menon, V. (2014) · Journal of the American College of Cardiology · doi:10.1016/s0735-1097(14)61335-8 · Cited by 3
Long-Term Effects of Intensive Glucose Lowering on Cardiovascular Outcomes
Schinner, S. (2011) · Yearbook of Medicine · doi:10.1016/s0084-3873(11)00369-5 · Cited by 3
Burns, R. B., Graham, K. L., Sawhney, M., & Reynolds, E. E. (2017) · Annals of Internal Medicine · doi:10.7326/m17-2162 · Cited by 3
The Role of Diet in the Prevention and Treatment of Cardiovascular Disease
Skulas‐Ray, A. C., Flock, M. R., & Kris‐Etherton, P. M. (2012) · Elsevier eBooks · doi:10.1016/b978-0-12-391884-0.00029-9 · Cited by 5
Cardiovascular Disease and Chronic Kidney Disease
Parfrey, P. S., & Barrett, B. J. (2014) · Elsevier eBooks · doi:10.1016/b978-0-12-411602-3.00016-0 · Cited by 3
Hüseyınoğlu, Ü., Ülker, K., Temur, İ., & Kütük, M. (2011) · Kafkas Journal of Medical Sciences · doi:10.5505/kjms.2011.02486 · Cited by 7
Marahrens, L., Röck, D., Ziemssen, T., Kern, R., Ziemssen, F., & Fritsche, A. (2017) · DMW - Deutsche Medizinische Wochenschrift · doi:10.1055/s-0043-111388 · Cited by 5
“[95% Konfidenzintervall] [52,7; 63,2] [53,2; 59,0] [50,3; 54,7] [48,5; 51,4]”
BackgroundKobalava, Z. D., & Kiyakbaev, G. (2018) · Kardiologiia · doi:10.18087/cardio.2018.1.10082 · Cited by 4
“Причем данные по расширенному наблюдению в исследовании ACCORD не подтвердили гипотезу о том, что более высокая смертность связана с тяжелой гипогликемией, частота которой была закономерно выше в группе интенсивного контроля гликемии [20].”
Testai, F. D., & Gorelick, P. B. (2016) · Springer eBooks · doi:10.1007/978-3-319-29152-9_15 · Cited by 4
Intensive Glucose Lowering and Cardiovascular Outcomes
Fan, Y., Zhang, A., & Xiao, Y. (2011) · New England Journal of Medicine · doi:10.1056/nejmc1103669 · Cited by 3
Management of type 2 diabetes mellitus and prediction of cardiovascular complications
van Dieren, S., Health, C., Health, J. O. C., Economics, E. &. H., van der Schouw, Y. T., Beulens, J. W. J., & Peelen, L. M. (2013) · Utrecht University Repository (Utrecht University) · Cited by 5
Bariatric surgery and fractures
Bueter, M. (2016) · BMJ · doi:10.1136/bmj.i4057 · Cited by 3
Editorial: Cross Talk Between the Immune System and Metabolism
Chen, J., Kong, W., & Zhong, J. (2020) · Frontiers in Endocrinology · doi:10.3389/fendo.2020.00588 · Cited by 3
“Intensive antidiabetic therapy in diabetic patients may cause hypoglycemia, which has been found to be associated with an increased risk for adverse cardiovascular outcomes and all-cause mortality (9).”
BackgroundLi, M.-C., Zhang, J., Li, H., Li, Y., Wang, C., Zhu, H., & Liu, Z. (2025) · Journal of the American Nutrition Association · doi:10.1080/27697061.2025.2540940 · Cited by 2
Liu, M., Xiang, S., & Hu, X. (2025) · World Journal of Diabetes · doi:10.4239/wjd.v16.i8.108839 · Cited by 3
Liu, M., Pei, J., Zeng, C., Xin, Y., Tang, P., & Hu, X. (2025) · Nutrition Journal · doi:10.1186/s12937-025-01251-0 · Cited by 2
The Cardiovascular Effects of Acute and Chronic Hypoglycemia
Dintakurti, A., Parikh, M. A., Silver, R., Frishman, W. H., & Peterson, S. J. (2025) · Cardiology in Review · doi:10.1097/crd.0000000000001114 · Cited by 2
Margolis, K. L., & O’Connor, P. J. (2012) · Archives of Internal Medicine · doi:10.1001/archinternmed.2012.1775 · Cited by 2
Comment mesure-t-on le bénéfice net d’un traitement ?
Gueyffier, F., Piedbois, P., Bergmann, J., Avouac, B. P., Borel, T., Boussageon, R., Brun-Strang, C., Braunstein, D., Cazeneuve, B., Diviné, M., et al. (2017) · Therapies · doi:10.1016/j.therap.2016.11.057 · Cited by 2
Prevention of Cardiovascular Disease in Patients with Chronic Kidney Disease
Lo, R. H., & Glassock, R. J. (2020) · Contemporary cardiology · doi:10.1007/978-3-030-56279-3_25 · Cited by 2
Fuentes, B., Amaro, S., de Leciñana, M. A., Arenillas, J. F., Martín, Ó. A., Castellanos, M., Freijo, M., García-Pastor, Gomis, M., Choco, M. G., et al. (2021) · Neurología (English Edition) · doi:10.1016/j.nrleng.2020.04.022 · Cited by 11
Kyavar, M., & Alemzadeh‐Ansari, M. J. (2021) · Elsevier eBooks · doi:10.1016/b978-0-323-80915-3.00026-0 · Cited by 3
Lacerda, M. C. C., Bacelar, J. A., dos Santos, T. A., Silva, N. R., Café, J. F., Pierote, G. F., Silva, T. P., & Moura, N. R. F. (2022) · Research Society and Development · doi:10.33448/rsd-v11i15.37183 · Cited by 2
Bonifant, G. C., & Weir, M. R. (2022) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfac313 · Cited by 3
Type 2 Diabetes-Etiology, Epidemiology, Pathogenesis, Treatment
Burns, C., & Francis, N. (2023) · Springer eBooks · doi:10.1007/978-3-319-12125-3_34-3 · Cited by 3
Jiao, T., Kianmehr, H., Lin, Y., Li, P., Ospina, N. S., Ghayee, H. K., Ruzieh, M., Fonseca, V. A., Shi, L., Zhang, P., et al. (2024) · Diabetes Obesity and Metabolism · doi:10.1111/dom.15453 · Cited by 3
“11,19,20 The average age of participants was 62.8 years, and on average they had been followed for 3.5 years.”
BackgroundInfluentialPandya, N., & Patel, M. (2024) · Springer eBooks · doi:10.1007/978-3-030-74720-6_38 · Cited by 2
Alqahtani, F. M. A., Binghamiah, A. S. M., Al-Qahtani, A., Alqahtani, A., Alorfi, Y. A., Alqahtani, R. S., Alqahtani, M. S., & Alshahrani, A. A. (2024) · Cureus · doi:10.7759/cureus.72374 · Cited by 4
HbA 1c : Chasing numbers or considering context?
Dunning, T. L., & Cukier, K. (2014) · Figshare · Cited by 2
HbA1c pour le diagnostic et le suivi du diabète: Le point de vue du diabétologue
Larger, É., Lemoine, A. Y., Gonfroy‐Leymarie, C., & Borie‐Swinburne, C. (2012) · Revue Francophone des Laboratoires · doi:10.1016/s1773-035x(12)71326-6 · Cited by 2
Krempf, M. (2013) · Médecine des Maladies Métaboliques · doi:10.1016/s1957-2557(13)70594-7 · Cited by 3
Diabetes mellitus, insulin, oral antidiabetes agents, obesity
Evans, M. L. (2012) · Elsevier eBooks · doi:10.1016/b978-0-7020-4084-9.00075-6 · Cited by 5
Fritsche, A., Hahn, A., Landgraf, W., & Häring, H. (2010) · touchREVIEWS in Endocrinology · doi:10.17925/ee.2013.09.01.1 · Cited by 2
Doménech, M., Camafort, M., & Coca, A. (2016) · Updates in hypertension and cardiovascular protection · doi:10.1007/978-3-319-32074-8_13 · Cited by 2
Tolba, M. K. A., Elkhashab, K., & Said, A. S. A. (2016) · International Journal of Pharmacy and Pharmaceutical Sciences · doi:10.22159/ijpps.2017v9i1.15496 · Cited by 2
Kardiovaskuläre Effekte antidiabetischer Therapie
Laubner, K., & Seufert, J. (2017) · DMW - Deutsche Medizinische Wochenschrift · doi:10.1055/s-0043-100564 · Cited by 2
Bordier, L., Sollier, M., Dolz, M., Garcia, C., Allain, J., & Bauduceau, B. (2019) · Médecine des Maladies Métaboliques · doi:10.1016/s1957-2557(19)30022-7 · Cited by 3
Key Concepts in Screening for Depression in People with Diabetes
Holt, R. I. G., & Feltz-Cornelis, C. M. V. D. (2012) · Springer eBooks · doi:10.1007/978-0-85729-751-8_3 · Cited by 2
(SFD), U. P. D. P. P. P. L. S. F. D. D. (2012) · Médecine des Maladies Métaboliques · doi:10.1016/s1957-2557(12)70660-0 · Cited by 2
Long-Term Effects of Intensive Glucose Lowering on Cardiovascular Outcomes
Oetjen, E. (2012) · Yearbook of Endocrinology · doi:10.1016/j.yend.2012.04.001 · Cited by 2
Cardiodiabetology: newer pharmacologic strategies for reducing cardiovascular disease risks
Wong, N. D. (2022) · Canadian Journal of Physiology and Pharmacology · doi:10.1139/cjpp-2022-0065 · Cited by 2
From a Glycocentric Approach to Prevention of Multi-Organ Damage in Type 2 Diabetes
Grover‐Páez, F., Gómez, A. M., Suárez, A., & Echauri, A. M. (2023) · IntechOpen eBooks · doi:10.5772/intechopen.1002363 · Cited by 2
Lee, S., Liu, T., Chung, C. T., Reinhold, J., Vassiliou, V. S., & Tse, G. (2024) · npj Metabolic Health and Disease · doi:10.1038/s44324-024-00012-7 · Cited by 3
“22, p = 0.04)thantheircounterpartsinthestandardglycemiccontrol group,withagreaterincidenceofsigni fi cantweightgainandhypoglycemia, resulting in early termination of the trial 2 .”
InfluentialTreatment of albuminuria due to diabetic nephropathy: recent trial results
Horwitz, E. J., & Schelling, J. R. (2014) · Clinical Investigation · doi:10.4155/cli.14.19 · Cited by 3
Sawada, T., Uzu, K., Hashimoto, N., Onishi, T., Takaya, T., Takaya, T., Shimane, A., Taniguchi, Y., Yasaka, Y., Ohara, T., et al. (2019) · doi:10.35248/2155-6156.19.10.827 · Cited by 2
“Rather, there is concern that intensive glucose control may be associated with adverse cardiovascular outcomes [24,25].”
Diabète de type 2 : les médicaments hypoglycémiants et leurs risques cardiovasculaires
Bauduceau, B., & Bordier, L. (2017) · Bulletin de l Académie Nationale de Médecine · doi:10.1016/s0001-4079(19)30390-5 · Cited by 2
Clostridium difficileInfection and Colonization
Lapane, K. L., Motzkus, C., & Pakyz, A. L. (2012) · New England Journal of Medicine · doi:10.1056/nejmc1113861 · Cited by 2
Coronary artery disease screening using coronary computed tomography angiography.
Potier, L., Matallah, N., & Mohammedi, K. (2015) · Journal of the American Medical Association (JAMA) · doi:10.1001/jama.2015.1429 · Cited by 2
Cardiovascular outcome trials of glucose-lowering strategies in type 2 diabetes
Vaccaro, O., Masulli, M., Bonora, E., Prato, S. D., & Riccardi, G. (2014) · The Lancet · doi:10.1016/s0140-6736(14)61672-x · Cited by 2
Metadata
- Authors
- The ACCORD Study Group
- Affiliations
- McMaster University (CA)
- Corresponding author
- The ACCORD Study Group
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2011-03-03
- Volume
- 364
- Issue
- 9
- Pages
- 818-828
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- PMC
- PMC4083508
- OpenAlex
- W2125468958
- Cited by
- 1,035
- References
- 18
- Citations by year
- 2026: 12 · 2025: 33 · 2024: 27 · 2023: 35 · 2022: 29 · 2021: 61 · 2020: 51 · 2019: 53 · 2018: 81 · 2017: 78 · 2016: 80 · 2015: 91 · 2014: 100 · 2013: 108 · 2012: 120
- FWCI
- 104.55
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- Funders
- National Institutes of Health (n01hc95183-23-0-0, n01hc95180-24-0-1, n01hc95184-24-0-1, n01hc95181-23-0-1, n01hc95182-23-0-1, n01hc95178-28-0-1, n01hc95179-25-0-0)
- National Heart, Lung, and Blood Institute (N01- HC-95181, N01 HC095184, N01-HC- 95180, N01-HC-95178, N01 HC095182, N01 HC095181, Y01 HC001010, Y1-HC-9035, N01-HC-095183, N01 HC095178, N01-HC-95184, N01HC95179, N01 HC095180, Y01 HC009035, Y1-HC-1010, N01‐HC‐95183, N01-HC-95182, N01 HC095179)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Keywords
- type 2 diabetes, HbA1c, cardiovascular outcomes, mortality, myocardial infarction, stroke, cardiovascular disease, glycemic targets, hypoglycemia, adverse events, long-term follow-up, EXSCEL trial
- MeSH terms
- Adult, Aged, Cardiovascular Diseases, Diabetes Mellitus, Type 2, Female, Follow-Up Studies, Glycated Hemoglobin, Humans, Hypoglycemic Agents, Male, Middle Aged, Myocardial Infarction, Proportional Hazards Models, Treatment Outcome, Stroke, Kaplan-Meier Estimate
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.